The Precision Peptide Company Inc.
BPC
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 31.70K | 31.60K | 4.30K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.70K | 31.60K | 4.30K | -- | -- |
| Cost of Revenue | 5.50K | 18.60K | 1.40K | -- | -- |
| Gross Profit | 26.20K | 12.90K | 2.90K | -- | -- |
| SG&A Expenses | 1.06M | 771.10K | 453.80K | 187.60K | 139.60K |
| Depreciation & Amortization | -- | 33.30K | 32.70K | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.09M | 842.20K | 487.90K | 187.60K | 139.60K |
| Operating Income | -1.06M | -810.70K | -483.60K | -187.60K | -139.60K |
| Income Before Tax | -1.03M | -2.45M | -481.70K | -222.10K | -139.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.03M | -2.45M | -481.70K | -222.10K | -139.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.03M | -2.45M | -481.70K | -222.10K | -139.60K |
| EBIT | -1.06M | -810.70K | -483.60K | -187.60K | -139.60K |
| EBITDA | -1.04M | -777.30K | -472.70K | -187.00K | -138.90K |
| EPS Basic | -0.03 | -0.05 | -0.02 | -0.01 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.03 | -0.05 | -0.02 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 40.48M | 45.44M | 28.24M | 17.33M | 7.71M |
| Average Diluted Shares Outstanding | 40.48M | 45.44M | 28.24M | 17.33M | 7.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |